The Emergent BioSolutions (NYSE:EBS) share price has done well in the last month, posting a gain of 32%. Zooming out...
The stock of Emergent BioSolutions (NYSE: EBS) has been on fire of late. The company has been involved in the race to develop a vaccine for COVID-19. Specifically, Emergent signed several contract development and manufacturing agreements with other companies that are currently developing vaccines for the coronavirus.
Emergent BioSolutions and Johnson & Johnson signed a $135 million accord to produce J&J;'s lead candidate for a vaccine against coronavirus.
Reaffirms full year 2020 financial forecastExecutes multi-faceted response to COVID-19 drawing upon longstanding investments in capabilities to address public health threats, as.
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Emergent BioSolutions Inc. (EBS) announced today that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 21, 2020 at 9:00 AM EDT. The Company, which disclosed the move to virtual-only format in all proxy materials related to the 2020 Annual Meeting of Stockholders, has taken this step to support the health and well-being of meeting participants in light of the COVID-19 pandemic. As described in the proxy materials, stockholders of record as of the record date of March 26, 2020 are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/EBS2020 and entering their 16-digit Control Number provided on the proxy card, voting instruction form or notice received from the Company to log into this website.
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Emergent BioSolutions Earnings Conference Call. My name is Bob Burrows. As is customary, today's call is open to all participants, and in addition, the call is being recorded and is copyrighted by Emergent BioSolutions.
The company recently ended up grabbing quite a bit of investor attention thanks to a recently announced partnership with Johnson & Johnson (NYSE: JNJ) to help manufacture the latter's COVID-19 vaccine. Over the past month, the company has signed agreements with a number of other COVID-19 vaccine makers as well. Does all this make Emergent BioSolutions the next hot coronavirus stock, one you should keep on your watch list?
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Emergent Biosolutions Inc. has been strong and could climb still further in the months ahead. In the daily bar chart of EBS, below, we can see that the stock made a seven-month consolidation pattern around $55 before its upside breakout. The On-Balance-Volume (OBV) line is in an uptrend from August and its rise tells us that buyers of EBS have been more aggressive for several months now.
On Mad Money Monday night, Jim Cramer spoke with Robert Kramer, CEO of Emergent BioSolutions Inc. , one of many vaccine makers in the race to stop Covid-19. Kramer said that Emergent has a long history of focusing on public health threats. In the daily bar chart of EBS, below, we can see that prices began a strong upside move in late August long before the words "coronavirus" and "pandemic" entered our vocabulary.
It's great to see Emergent BioSolutions (NYSE:EBS) shareholders have their patience rewarded with a 34% share price...
Johnson & Johnson tapped Emergent Biosolutions to help manufacture 1 billion doses of its experimental coronavirus vaccine — sending Emergent Biosolutions stock flying on Friday.
At its worst on March 23rd, Dow Jones and the S&P declined by around 37% and 34%. At the time, those kinds of numbers represented a loss of a 3-year gain since Trump’s election in November of 2016. Measured by VIX, market volatility spiked by 43% in March, reaching levels that are comparable to the […]
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
Q1 2020 Emergent BioSolutions Inc Earnings Call
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 150.00% and 1.28%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The entire world anxiously awaits good news in the race to develop a vaccine for novel coronavirus disease COVID-19. And there are plenty of drugmakers hoping to be the bearers of some good news, including both big pharmaceutical companies and small biotechs.
Which of these COVID-19 partners is the better pick? Here's how J&J; and Emergent stack up against each other.
GAITHERSBURG, Md., May 12, 2020 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the.